First Participant Enrolled in Moderna’s Phase 1 Epstein-Barr Virus Vaccine (mRNA-1189) Trial

Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska!
Posted in

Quality. Continuity. Velocity.